How has the acquisition of Allergan impacted AbbVie's financial performance?

The acquisition of Allergan, completed in May 2020, significantly boosted AbbVie's net revenues, which grew by 52.1% to $12.9 billion in the third quarter of 2020. This integration has created a more diversified company with leadership positions in multiple therapeutic areas, but it also brought increased operating costs and expenses, including substantial amortization of intangible assets and integration-related charges.

What is the outlook for AbbVie's key products and pipeline?

AbbVie's key growth drivers include strong performance from immunology products like Skyrizi and Rinvoq, alongside continued strength from Humira in the U.S. Hematologic oncology products like Imbruvica and Venclexta also show robust growth. The Allergan acquisition added significant products in aesthetics, neuroscience, and eye care. The company maintains a robust pipeline with approximately 80 compounds or indications in clinical development, focusing on key therapeutic areas.

How is AbbVie managing its debt and capital structure post-acquisition?

AbbVie financed the Allergan acquisition through a combination of cash and stock. The company has incurred significant debt to support the transaction, as reflected in the increase in interest expense. While the company has taken steps to manage its debt, including issuing new notes and repaying existing ones, investors should monitor its leverage ratios and credit ratings. AbbVie continues to prioritize returning cash to shareholders through dividends and stock repurchases.

What is the potential impact of COVID-19 on AbbVie's business?

AbbVie has stated that while the impact of COVID-19 on its operations has not been material to date, the situation remains uncertain. The pandemic could continue to negatively impact results of operations due to factors such as lower new patient starts across its therapeutic portfolio. The company is actively managing its supply chain and has partnered with global authorities to explore potential treatments for COVID-19.

ABBV 10-Q Quarterly Report Q3 FY2020 — Revenue, Net Income, EPS

Summary

AbbVie Inc. reported strong revenue growth in the third quarter of 2020, driven significantly by the recently completed acquisition of Allergan. Net revenues surged to $12.9 billion, a substantial increase from $8.5 billion in the prior year period, largely due to the inclusion of Allergan's operations. Despite the revenue uplift, the company faced increased operating costs and expenses, including significant amortization of intangible assets and integration costs related to the Allergan acquisition. Diluted earnings per share (EPS) for the quarter were $1.29, showing a slight increase from $1.26 in the prior year, however, this figure includes substantial one-time charges and non-cash expenses. Excluding these, the operational performance might present a different picture. Investors should focus on the revenue diversification achieved through the Allergan merger and monitor the integration progress and synergy realization to gauge the long-term impact on profitability and shareholder value. The company also reiterated its commitment to returning capital to shareholders with a planned dividend increase.

Financial Highlights

56 data points

Beta

Revenue

$12.90B

0.6% Gross Margin

Net Income

$2.31B

0.2% Net Margin

EPS (Diluted)

$1.29

Total Assets

$149.62B

Cash & Equivalents

$7.89B

Free Cash Flow

$5.61B

Financial Statements

Beta

Revenue	$12.90B
Cost of Revenue	$5.05B
Gross Profit	$7.85B
SG&A Expenses	$2.85B
Operating Expenses	$9.65B
Operating Income	$3.25B
Interest Expense	$630.00M
Net Income	$2.31B
EPS (Basic)	$1.30
EPS (Diluted)	$1.29
Shares Outstanding (Basic)	1.77B
Shares Outstanding (Diluted)	1.77B

Key Highlights

1AbbVie completed the acquisition of Allergan on May 8, 2020, significantly expanding its diversified product portfolio across immunology, oncology, aesthetics, neuroscience, and eye care.
2Total net revenues for the third quarter of 2020 increased by 52.1% to $12.9 billion, largely driven by the inclusion of Allergan's operations.
3For the nine months ended September 30, 2020, net revenues grew by 30.7% to $31.9 billion.
4Diluted earnings per share (EPS) for the third quarter of 2020 were $1.29, an increase from $1.26 in the prior year period.
5Operating earnings for the third quarter were $3.3 billion, up from $2.6 billion in the prior year, but impacted by increased operating costs and expenses.
6The company continues to invest heavily in research and development, with pipeline assets across immunology, oncology, aesthetics, neuroscience, eye care, and women's health.
7AbbVie announced a planned increase in its quarterly cash dividend from $1.18 to $1.30 per share, demonstrating a commitment to returning capital to shareholders.

AbbVie Inc. Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions